Celgene Corporation (NASDAQ:CELG) had its price objective lifted by stock analysts at Mizuho from $134.00 to $158.00 in a note issued to investors on Friday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s target price suggests a potential upside of 12.42% from the company’s current price.

Other analysts have also issued reports about the company. Vetr lowered Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective for the company. in a research report on Tuesday, August 29th. Cantor Fitzgerald reiterated a “buy” rating on shares of Celgene Corporation in a research report on Monday, August 28th. BTIG Research reiterated a “buy” rating and issued a $138.00 price objective on shares of Celgene Corporation in a research report on Wednesday, May 24th. Bank of America Corporation reiterated a “buy” rating on shares of Celgene Corporation in a research report on Wednesday. Finally, Argus upgraded Celgene Corporation from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $96.93 to $160.00 in a research report on Monday, July 31st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $148.27.

Shares of Celgene Corporation (CELG) opened at 140.55 on Friday. The firm has a market capitalization of $109.96 billion, a P/E ratio of 43.53 and a beta of 1.89. Celgene Corporation has a one year low of $96.93 and a one year high of $142.64. The firm has a 50-day moving average of $134.74 and a 200-day moving average of $127.31.

Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same period last year, the company posted $1.44 earnings per share. The firm’s quarterly revenue was up 18.7% compared to the same quarter last year. On average, equities analysts predict that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/09/15/celgene-corporation-celg-price-target-increased-to-158-00-by-analysts-at-mizuho.html.

In other Celgene Corporation news, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total value of $1,309,430.00. Following the sale, the director now owns 85,551 shares in the company, valued at approximately $12,110,599.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ernest Mario sold 18,506 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the sale, the director now owns 69,424 shares in the company, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. Insiders sold a total of 267,476 shares of company stock worth $35,812,841 in the last 90 days. Company insiders own 0.95% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its stake in Celgene Corporation by 5.7% in the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after acquiring an additional 3,084,227 shares in the last quarter. Vanguard Group Inc. lifted its stake in Celgene Corporation by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after acquiring an additional 1,610,056 shares in the last quarter. State Street Corp lifted its stake in Celgene Corporation by 2.3% in the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after acquiring an additional 723,844 shares in the last quarter. BlackRock Institutional Trust Company N.A. lifted its stake in Celgene Corporation by 2.3% in the 3rd quarter. BlackRock Institutional Trust Company N.A. now owns 20,712,785 shares of the biopharmaceutical company’s stock valued at $2,165,107,000 after acquiring an additional 471,143 shares in the last quarter. Finally, Jennison Associates LLC lifted its stake in Celgene Corporation by 14.1% in the 3rd quarter. Jennison Associates LLC now owns 15,921,002 shares of the biopharmaceutical company’s stock valued at $1,664,222,000 after acquiring an additional 1,967,645 shares in the last quarter. Hedge funds and other institutional investors own 79.43% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.